{
    "name": "vitamin E",
    "comment": "OTC",
    "other_names": [
        "Aquasol E",
        "alpha-tocopherol",
        "tocopherol"
    ],
    "classes": [
        "Vitamins",
        "Fat-Soluble"
    ],
    "source": "https://reference.medscape.com/drug/aquasol-e-alpha-tocopherol-vitamine-344429",
    "pregnancy": {
        "common": [
            "Pregnancy Category: A (RDA levels)",
            "Lactation: Excreted in breast milk; safe"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Excreted in breast milk; safe"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to vitamin E or formulation components"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Vitamin E, at RDA levels, does not increase bleeding time or affect warfarin except at megadoses (~10x RDA or higher) - adjustment of warfarin may be necessary for such doses",
                "Discontinue high dose Vitamin E supplementation 1 month before surgery, may resume after recovery",
                "May induce vitamin K deficiency; use with caution in Vitamin K deficiency, bleeding propensity or lesions (bleeding peptic ulcers, hemophilia etc)",
                "High doses of vitamin E (â‰¥400 units daily) administered long-term administration (>1 year) may increase all-cause mortality"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betrixaban",
            "description": {
                "common": "vitamin E, betrixaban.\nEither increases levels of the other by anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferric maltol",
            "description": {
                "common": "vitamin E decreases levels of ferric maltol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferrous sulfate",
            "description": {
                "common": "vitamin E decreases levels of ferrous sulfate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iron sucrose",
            "description": {
                "common": "vitamin E decreases levels of iron sucrose by increasing hepatic clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "polysaccharide iron",
            "description": {
                "common": "vitamin E decreases levels of polysaccharide iron by increasing hepatic clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selumetinib",
            "description": {
                "common": "vitamin E and selumetinib both increase  Other (see comment). Modify Therapy/Monitor Closely. Selumetinib contains vitamin E. Daily vitamin E intake (ie, amount in selumetinib, supplement, dietary) that exceeds recommendations may increase bleeding risk. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vortioxetine",
            "description": {
                "common": "vitamin E, vortioxetine.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "vitamin E increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zanubrutinib",
            "description": {
                "common": "vitamin E, zanubrutinib.\nEither increases effects of the other by anticoagulation. Modify Therapy/Monitor Closely. Zanubrutinib-induced cytopenias increases risk of hemorrhage. Coadministration of zanubritinib with antiplatelets or anticoagulants may further increase this risk."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alfalfa",
            "description": {
                "common": "alfalfa decreases levels of vitamin E by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. (Vitamin E)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "vitamin E, antithrombin alfa. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Vitamin E at RDA does not change INR in pts. on chronic warfarin therapy; megadoses (~10x RDA) may enhance anticoagulant effects in vitamin K deficient pts."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "vitamin E, antithrombin III. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Vitamin E at RDA does not change INR in pts. on chronic warfarin therapy; megadoses (~10x RDA) may enhance anticoagulant effects in vitamin K deficient pts."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "argatroban",
            "description": {
                "common": "vitamin E, argatroban. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Vitamin E at RDA does not change INR in pts. on chronic warfarin therapy; megadoses (~10x RDA) may enhance anticoagulant effects in vitamin K deficient pts."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bemiparin",
            "description": {
                "common": "vitamin E, bemiparin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Vitamin E at RDA does not change INR in pts. on chronic warfarin therapy; megadoses (~10x RDA) may enhance anticoagulant effects in vitamin K deficient pts."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "vitamin E, bivalirudin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Vitamin E at RDA does not change INR in pts. on chronic warfarin therapy; megadoses (~10x RDA) may enhance anticoagulant effects in vitamin K deficient pts."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "busulfan",
            "description": {
                "common": "vitamin E, busulfan. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "capecitabine",
            "description": {
                "common": "vitamin E, capecitabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbonyl iron",
            "description": {
                "common": "vitamin E decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carboplatin",
            "description": {
                "common": "vitamin E, carboplatin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carmustine",
            "description": {
                "common": "vitamin E, carmustine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chitosan",
            "description": {
                "common": "chitosan decreases levels of vitamin E by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorambucil",
            "description": {
                "common": "vitamin E, chlorambucil. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cisplatin",
            "description": {
                "common": "vitamin E, cisplatin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cladribine",
            "description": {
                "common": "vitamin E, cladribine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cytarabine",
            "description": {
                "common": "vitamin E, cytarabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dacarbazine",
            "description": {
                "common": "vitamin E, dacarbazine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dalteparin",
            "description": {
                "common": "vitamin E, dalteparin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Vitamin E at RDA does not change INR in pts. on chronic warfarin therapy; megadoses (~10x RDA) may enhance anticoagulant effects in vitamin K deficient pts."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "decitabine",
            "description": {
                "common": "vitamin E, decitabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "docetaxel",
            "description": {
                "common": "vitamin E, docetaxel. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "vitamin E, enoxaparin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Vitamin E at RDA does not change INR in pts. on chronic warfarin therapy; megadoses (~10x RDA) may enhance anticoagulant effects in vitamin K deficient pts."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethanol",
            "description": {
                "common": "ethanol decreases levels of vitamin E by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ferrous fumarate",
            "description": {
                "common": "vitamin E decreases levels of ferrous fumarate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ferrous gluconate",
            "description": {
                "common": "vitamin E decreases levels of ferrous gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "floxuridine",
            "description": {
                "common": "vitamin E, floxuridine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fludarabine",
            "description": {
                "common": "vitamin E, fludarabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluorouracil",
            "description": {
                "common": "vitamin E, fluorouracil. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "vitamin E, fondaparinux. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Vitamin E at RDA does not change INR in pts. on chronic warfarin therapy; megadoses (~10x RDA) may enhance anticoagulant effects in vitamin K deficient pts."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gemcitabine",
            "description": {
                "common": "vitamin E, gemcitabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "heparin",
            "description": {
                "common": "vitamin E, heparin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Vitamin E at RDA does not change INR in pts. on chronic warfarin therapy; megadoses (~10x RDA) may enhance anticoagulant effects in vitamin K deficient pts."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "vitamin E, ifosfamide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "irinotecan",
            "description": {
                "common": "vitamin E, irinotecan. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "irinotecan liposomal",
            "description": {
                "common": "vitamin E, irinotecan liposomal. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iron dextran complex",
            "description": {
                "common": "vitamin E decreases levels of iron dextran complex by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lomustine",
            "description": {
                "common": "vitamin E, lomustine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "vitamin E, mechlorethamine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "melphalan",
            "description": {
                "common": "vitamin E, melphalan. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mercaptopurine",
            "description": {
                "common": "vitamin E, mercaptopurine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mineral oil",
            "description": {
                "common": "mineral oil decreases levels of vitamin E by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nelarabine",
            "description": {
                "common": "vitamin E, nelarabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "orlistat",
            "description": {
                "common": "orlistat decreases levels of vitamin E by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. May cause fat-soluble vitamin malabsorption. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "vitamin E, oxaliplatin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paclitaxel",
            "description": {
                "common": "vitamin E, paclitaxel. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paclitaxel protein bound",
            "description": {
                "common": "vitamin E, paclitaxel protein bound. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentostatin",
            "description": {
                "common": "vitamin E, pentostatin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenindione",
            "description": {
                "common": "vitamin E, phenindione. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Vitamin E at RDA does not change INR in pts. on chronic warfarin therapy; megadoses (~10x RDA) may enhance anticoagulant effects in vitamin K deficient pts."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pralatrexate",
            "description": {
                "common": "vitamin E, pralatrexate. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "protamine",
            "description": {
                "common": "vitamin E, protamine. Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown. Vitamin E at RDA does not change INR in pts. on chronic warfarin therapy; megadoses (~10x RDA) may enhance anticoagulant effects in vitamin K deficient pts."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rose hips",
            "description": {
                "common": "vitamin E decreases levels of rose hips by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "streptozocin",
            "description": {
                "common": "vitamin E, streptozocin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "thioguanine",
            "description": {
                "common": "vitamin E, thioguanine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "thiotepa",
            "description": {
                "common": "vitamin E, thiotepa. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "topotecan",
            "description": {
                "common": "vitamin E, topotecan. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "treosulfan",
            "description": {
                "common": "vitamin E, treosulfan. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vinblastine",
            "description": {
                "common": "vitamin E, vinblastine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vincristine",
            "description": {
                "common": "vitamin E, vincristine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vincristine liposomal",
            "description": {
                "common": "vitamin E, vincristine liposomal. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vinorelbine",
            "description": {
                "common": "vitamin E, vinorelbine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Fatigue",
            "percent": "400"
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Flatulence",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Blurred vision",
            "percent": null
        },
        {
            "name": "Necrotizing enterocolitis",
            "percent": null
        },
        {
            "name": "infants",
            "percent": null
        },
        {
            "name": "Increased serum creatinine",
            "percent": null
        },
        {
            "name": "Increased risk of hemorrhagic stroke",
            "percent": null
        },
        {
            "name": "Recent evidence suggests that Vitamin E may suppress action of other antioxidants",
            "percent": null
        },
        {
            "name": "Very modest but statistically significant increase in all",
            "percent": null
        },
        {
            "name": "cause mortality with supplemental intake of vitamin E",
            "percent": null
        },
        {
            "name": "IU",
            "percent": null
        },
        {
            "name": "day",
            "percent": null
        }
    ]
}